8-K current report · filed Oct 20, 2026

Rapport Therapeutics, Inc. (RAPP) 8-K Current Report: October 20, 2026

Item 8.01Item EX-99.1Item EX-99.2Item 7.01RAPP overview

Short answer

Rapport Therapeutics, Inc. (RAPP) filed an 8-K current report with the SEC on October 20, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). Positive topline Phase 2 results announced for RAP-219 in bipolar mania.

Rapport Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Positive topline Phase 2 results announced for RAP-219 in bipolar mania
  • Conference call and webcast scheduled October 20, 2026 to discuss trial data
  • Investor presentation available through Rapport’s website and Exhibit 99.2

Item 8.01 · Other Events

  • Phase 2 met its primary endpoint: YMRS improvement 3.1 points versus placebo at Week 3, p=0.045
  • Secondary mania-severity endpoint also significant: 0.4-point improvement versus placebo, p=0.024
  • Safety broadly comparable with placebo: TEAEs 51.6% versus 52.8%, no serious adverse events
  • Development advances toward two Phase 3 bipolar-mania trials, pending FDA meeting targeted for Q1 2027
  • Cash $436.1M as of June 30, 2026, expected to fund operations into the second half of 2029

Item EX-99.1 · Exhibit EX-99.1

  • Phase 2 met primary and secondary endpoints: YMRS improvement 3.1 points versus placebo, p=0.045, CGI-BP improvement 0.4 points, p=0.024
  • RAP-219 reduced YMRS 15.4 points from baseline versus 12.3 points for placebo at Week 3
  • Safety profile favorable: TEAEs 51.6% versus 52.8% placebo, no severe or serious adverse events
  • Discontinuations due to TEAEs remained higher with RAP-219, 3.2% versus 0.8% placebo
  • FDA End-of-Phase 2 meeting expected Q1 2027, with two Phase 3 bipolar mania trials targeted for the second half of 2027

Item EX-99.2 · Exhibit EX-99.2

  • Phase 2 bipolar mania trial met primary and secondary endpoints, supporting RAP-219 advancement into Phase 3
  • YMRS improvement 3.1 points versus placebo at Week 3, p=0.045, with RAP-219 improvement of 15.4 points
  • CGI-BP-S improvement 0.4 points versus placebo, p=0.024, indicating benefit across independent mania measures
  • Similar TEAE incidence, 51.6% RAP-219 versus 52.8% placebo, with no severe TEAEs or SAEs
  • End-of-Phase 2 FDA meeting expected 1Q 2027, Phase 3 initiation anticipated 2H 2027, cash $436.1M supporting runway into 2H 2029

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Rapport Therapeutics, Inc. 8-K filings

Get the next RAPP 8-K as it lands

Follow RAPP for push alerts, or ask the research agent what this filing means.